New Weight-Loss shot shows promise in major trial
NCT ID NCT06604624
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new weekly injection (HD1916) similar to semaglutide for weight loss in 462 obese adults without diabetes. Participants received the drug for 44 weeks, and researchers measured how much weight they lost and any side effects. The goal was to see if this treatment is safe and effective for managing obesity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can a daily probiotic boost metabolic health and body confidence?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?